We are committed to participate in making medicines accessible to more and more people around the world. We will ensure that the development of Indigene is integrated into a strategy targeting strong, sustainable, and profitable growth.

We leverage our proprietary Multiceutics® approach to rapidly design and develop unique drugs with enhanced efficacy through synergistic pharmacology. The result is Smarter Medicines. We believe that Indigene is at the forefront of an emerging trend in the pharmaceutical industry—to develop drugs that synergistically modulate multiple pharmacological pathways associated with disease conditions. Our well-differentiated business model is focused on delivering innovation across the commercial value chain.

Combining our vision, passion, and commitment with our customer- and product-focused business model, we have made significant advances in building and delivering our value proposition. This includes our extensive knowledge base and proprietary Multiceutics product development approach, that we use to effectively develop an intellectual property backed portfolio of Prescription (Rx) and Consumer Health Care (CHC) products. In addition, we have introduced well-differentiated CHC products through our commercial presence in the US, and are preparing to launch products in Canada and other emerging markets.

The strong foundation of Indigene is based on our talented, committed global team that has the essential blend of experience and energy. Our board of directors and advisors include such visionary global leaders as Dr. R. A. Mashelkar, Dr. William A. Haseltine, Dr. Goverdhan Mehta, Dr. Nirmal K. Ganguly, Mr. N. Prasad, Mr. Homi R. Khusrokhan, and Dr. G. Alexander Fleming. We are further strengthened by our strategic alliance with the Tata Group, one of the most respected conglomerates in the world.

We are glad you are interested in taking a look at Indigene, and perhaps joining us in our journey.